Executive Function, Cognitive Impairment, Illness Perceptions, and Medication Adherence Among Heart Transplant Recipients

Overview

About this study

Nonadherence to immunosuppression is associated with an increased risk for organ rejection, allograft vasculopathy, and death (De Geest et al., 2014). Immunosuppression nonadherence has been found to be a factor in up to 90% of late acute rejection events that occur after the first year following transplant, and in 13% to 26% of deaths among heart transplant recipients in single-center research studies (De Geest et al., 2005). A prospective cohort study found that for individuals who were nonadherent after their first year following transplant, the risk of a negative clinical event was doubled (Dobbels et al., 2004). In addition to the significant clinical outcomes, nonadherence to the therapeutic regimen is also associated with increased healthcare costs (De Geest et al., 2005). Despite the importance of adherence to immunosuppression medications following heart transplantation for the prevention of graft rejection and preservation of graft function, medication nonadherence rates following heart transplantation in the literature range from 20% to as high as 37% (Leentje De Bleser et al., 2009; Dobbels et al., 2017).

Nonadherence may occur directly through the failure to recall the intention to take the medication as intended, or indirectly through illness representations that can be shaped by cognitive function. Time since transplant, perceptions related to the necessity of medications, and the perceived impact of transplantation on life are factors that have been associated with higher rates of nonadherence in some solid organ transplant recipient populations (De Geest et al., 2014; Massey et al., 2015). Pre-transplant medication nonadherence has been found to predict post-transplant nonadherence (De Geest et al., 2014). Heart transplant recipients are at unique risk for cerebral hypoxic injury both before transplantation as a result of pathophysiologic processes that can occur during heart failure and treatment with mechanical circulatory support devices (MCSD), and following transplant as a result of cardiopulmonary bypass, heart structural remodeling, and inflammatory processes (Acampa et al., 2016; Cho et al., 2017). These mechanisms and their impact on executive function and working memory potentially influence the ability to adhere after transplantation. Additionally, evaluation of these variables has become increasingly important to assess in the context of aging, with the majority of individuals undergoing transplantation in their 50s, and median survival extending past 11 years (Insel et al., 2006; McCurry, 2019; Stoehr et al., 2008). Evaluating the relationship between self-management behaviors like medication adherence and executive function in heart recipients may improve interventions designed to support the heart transplant patient.

The proposed dissertation research seeks to examine the relationships between executive function, cognitive impairment, illness representations, cerebral hypoxic injury mechanisms and medication adherence among heart transplant recipients. The purpose of this study is to increase knowledge about these relationships, with the goal of expanding insights into factors associated with non-adherence to immunosuppression following heart transplantation. This knowledge has the potential to inform the development of interventions to improve adherence.   A descriptive, cross-sectional design will be employed, with measures conducted via telephone to mitigate risk to participants.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Heart transplant recipients that are over six months past their transplantation surgery will be recruited. This criteria is based off of the Transplant Center’s requirement that individuals have a caregiver for the first 3 months following transplantation to assist with self-management behaviors like medication adherence, and the Transplant Center’s medication weaning protocol wherein individuals are retained on higher doses of corticosteroids that may impact cognitive processes for the first 5 months following transplantation. 
  • Participants must be able to read, write, and understand English given the format of the measures that will be employed.
  • Once enrolled in the study, participants will complete a series of measures via a one-hour long recorded phone call.

Exclusion Criteria: 

  • Individuals with a confirmed diagnosis of dementia.
  • Active substance abuse given its potential impact on cognitive function.
  • Individuals that receive medications in an assisted living or skilled nursing facility setting.
  • Women who are pregnant or attempting to become pregnant.
  • Participants may not be admitted to the hospital during data collection, as this may interfere with their ability to recall medication adherence prior to the admission.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Stacy Al-Saleh, Ph.D., R.N., C.C.T.C.

Closed for enrollment

Contact information:

Stacy Al-Saleh Ph.D., R.N., C.C.T.C.

(480) 342-1010

Al-Saleh.Stacy@mayo.edu

More information

Publications

Publications are currently not available